Showing 3601-3610 of 7113 results for "".
- Bempikibart Shows Durable Responses, Post-Dosing Cessation for Severe AAhttps://practicaldermatology.com/news/Bempikibart-Shows-Durable-Responses-Post-Dosing-Cessation-Severe-AA/2471651/A novel IL-7/TSLP bifunctional receptor agonist has shown long-term durable responses and post-dosing cessation for patients with severe or very severe alopecia areata, according to a presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, by Brett King,
- Benzene Update at AAD Discusses Both Regulations and Health Riskshttps://practicaldermatology.com/news/Benzene-Update-AAD-Discusses-Both-Regulations-Health-Risks/2471605/Christopher Bunick, MD, PhD, FAAD, made waves at the 2024 American Academy of Dermatology (AAD) Annual Meeting with his presentation about benzene in benzoyl peroxide (BPO) products for acne treatments. At the 2025 AAD Annual Meeting in Orlando, Florida, Dr. Bunick provided an update on the resea
- New Baricitinib AA Data for Adolescents Could Be 'Game-Changing'https://practicaldermatology.com/news/New-Baricitinib-AA-Data-Adolescents-Could-Be-Game-Changing/2471600/Patients ages 12 to under 18 with severe alopecia areata (AA) treated with once-daily, oral baricitinib 4 mg and 2 mg saw clinically meaningful improvements in hair regrowth on the scalp, eyebrows, and eyelashes at Week 36 in the Phase 3 BRAVE-AA-PEDS study, presented as a late-breaker at the 202
- Report: L'Oreal Recalling BPO Product Due to Benzenehttps://practicaldermatology.com/news/Report-LOreal-Recalling-BPO-Product-Due-Benzene/2471598/L’Oreal SA is recalling La Roche-Posay’s benzoyl peroxide acne treatment, Effaclar Duo, in the US because of “concern that the creams are contaminated with benzene,” Bloomberg News reported. L’Oreal said testing found trace levels of benzene in one lot product, according to Bloomberg.
- New Spesolimab Data Indicate Impact on Both Physical, Mental Healthhttps://practicaldermatology.com/news/New-Spesolimab-Data-Indicate-Impact-Both-Physical-Mental-Health/2471581/New analyses of the effects of spesolimab on the physical symptoms and mental health burden associated with generalized pustular psoriasis (GPP) were presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. These post-hoc exploratory analyses from the
- Biologics, JAKs, and More Cited as Potential Treatments for CPUOhttps://practicaldermatology.com/news/Biologics-JAKis-More-Cited-Potential-Treatments-CPUO/2471552/New therapies for chronic pruritus of unknown origin (CPUO) could be close, Gil Yosipovitch, MD, said during his presentation, “What’s Best and What’s Next for Systemic Itch and CPUO” at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. “These are patients
- Study: 60% Lesion Clearance in Actinic Keratosis Patients Using Topical Bimiralisib Gelhttps://practicaldermatology.com/news/study-60-lesion-clearance-in-actinic-keratosis-patients-using-topical-bimiralisib-gel/2471542/Newly presented interim results from a phase 2 clinical trial evaluating bimiralisib topical gel (2%) saw more than half of patients with actinic keratosis achieving complete or partial lesion clearance. Bimiralisib, a pan-PI3
- Topical Gel Bimiralisib Shows Promise for AK in Interim Resultshttps://practicaldermatology.com/news/Topical-Gel-Bimiralisib-Shows-Promise-AK-Interim-Results/2471537/Interim results from an ongoing Phase 2 clinical trial in actinic keratosis highlighted strong potential for the safety and efficacy of topical gel bimiralisib, a selective pan-PI3K/mTOR inhibitor, Torqur AG announced at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Fl
- 2-Year Data: Bimekizumab Can Eliminate Draining Tunnels in HShttps://practicaldermatology.com/news/2-Year-Data-Bimekizumab-Can-Eliminate-Draining-Tunnels-HS/2471535/Two-year data from the BE HEARD trials for bimekizumab-bkzx (BIMZELX®) in moderate-to-severe hidradenitis suppurativa (HS) continued to demonstrate sustained disease control and durable relief from key HS symptoms, including the potential to help prevent long-term structural damage caused by drai
- Analysis: Biosimilars Show Comparable Effectiveness to Humira in Psoriasishttps://practicaldermatology.com/news/analysis-biosimilars-show-comparable-effectiveness-to-humira-in-psoriasis/2471496/Adalimumab biosimilars Amjevita and Imraldi showed similar effectiveness to Humira for the treatment of psoriasis in both new users and patients switching from Humira, according to an analysis of the British Association of Dermatologists Biologics and Immunomodulato